Cardiogeni Plc (CGNI) ORD GBP0.01

Sell:4.00pBuy:10.00pPrice unchangedNo change

Market closed |
Prices delayed by at least 15 minutes
Sell:4.00p
Buy:10.00p
Change:Price unchangedNo change
Deal now
Market closed |
Prices delayed by at least 15 minutes
Sell:4.00p
Buy:10.00p
Change:Price unchangedNo change
Market closed |
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Cardiogeni Plc, formerly Celixir Limited, is a United Kingdom-based clinical development stage bio-pharmaceutical company. The principal activity of the Company is the development and commercialization of a portfolio of novel cellular medicines for heart failure. The Company's platform technology enables the creation of unique (living) cells that are engineered with a therapeutic function. The Company's lead product, CLXR-001, is a patented engineered cellular medicine to treat heart failure patients which are administered during coronary artery bypass grafting surgery. CLXR-001 targets heart failure and consists of a novel allogeneic (off-the-shelf) cell type, iMP cells, engineered for cardiac regeneration.

Key people

Darrin Matthew Disley
Executive Chairman of the Board
Martin Evans
Chief Scientific Officer
Ajan Reginald
Executive Director
James Bethell
Independent Non-Executive Director
Chaim Hurvitz
Independent Non-Executive Director
Joanne Martin
Independent Non-Executive Director
Click to see more

Key facts

  • Shares in issue
    89.10m
  • EPIC
    CGNI
  • ISIN
    GB00BTBLFC12
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    £6.91m
  • Employees
    3
  • Exchange
    Aquis Stock Exchange
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.